Background: Current diagnostic methods, including
tumor markers such as alpha-fetoprotein (AFP),
carbohydrate antigen 19-9 (CA19-9), and
carcinoembryonic antigen (CEA), have limitations in
sensitivity and specificity, particularly in differentiating
Hepatocellular carcinoma (HCC) from chronic liver
diseases. This study investigated the diagnostic efficacy of
these markers, individually and in combination, using
chemiluminescence assay (CLIA) in patients with and
without HCC. Methods: A cross-sectional study design
was employed, analyzing data from 800 patients at Ibn
Sina Diagnostic and Imaging Center in Dhaka. Tumor
marker levels were assessed using CLIA kits, and
associations with HCC diagnosis, tumor differentiation,
occupation, age, and tumor size were examined. Results:
Descriptive statistics revealed higher tumor marker levels
in poorly differentiated tumors compared to welldifferentiated ones and controls. The combination of AFP,
CA19-9, and CEA showed superior diagnostic accuracy for
HCC, with a sensitivity of 86.5% and specificity of 92.3%. Occupation and age were found to correlate with tumor
marker levels and HCC risk, with certain occupations and
older age associated with larger tumor sizes. Regression
analysis confirmed the associations between tumor
markers and HCC. Conclusions: The study demonstrated
the potential of AFP, CA19-9, and CEA as a panel of tumor
markers for HCC detection and monitoring. CLIA emerged
as a reliable diagnostic tool, offering high specificity and
accuracy. Occupational factors and age were identified as
relevant considerations in HCC risk assessment.